Home Alzheimer’s Disease Utility of the 21-Gene Recurrence Score in Node-Positive Breast Cancer

Utility of the 21-Gene Recurrence Score in Node-Positive Breast Cancer

Introduction

Insights from gene expression profiling have vastly expanded our understanding of distinct molecular subtypes of breast cancer, and of tumor biology’s influence on response to therapy and outcomes. Efforts to develop genomic assays for clinical use have resulted in a new era of molecularly tailored breast cancer management. The Oncotype DX Breast Recurrence Score® (RS) analyzes gene expression using a reverse transcriptase-polymerase chain reaction method. After evaluating 250 candidate genes in archived tissue from node-negative (pN0) estrogen receptor–positive (ER+) patients, a panel of 21 genes (16 cancer-related genes and 5 reference genes) was selected.1-3 A proprietary algorithm produces a recurrence score of 0 to 100, with a higher score correlating to an increased risk of distant recurrence (DR). Substantial efforts have focused on demonstrating the clinical…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Lower-Dose Hypofractionated Radiotherapy Schedule Proves Effective for Patients With Locally Advanced Bladder Cancer

Using a hypofractionated schedule of 55 Gy in 20 fractions over 4 weeks to treat patients with locally advanced bladder cancer was noninferior to...

Study Identifies New Biomarker Which Could Predict Response to CD40 Immunotherapy in Pancreatic Cancer

Research published in JCI Insight identified systemic inflammation as a possible resistance mechanism to a CD40–based chemoimmunotherapy in patients with advanced pancreatic cancer.1According to...

Significant Interfacility Variation Found in Implementation of Low-Value Breast Cancer Procedures

A number of facility-level characteristics were associated with the use of low-value breast cancer procedures, and interfacility variation presented an opportunity for formal de-implementation...

KarMMa Trial Results for Ide-Cel in Refractory Myeloma Show Favorable Efficacy

Chimeric antigen receptor (CAR) T-cell therapy with idecabtagene vicleucel (ide-cel) induced responses in almost 75% of patients with multiple myeloma following relpase on multiple...

Recent Comments